Compare
Jasper Therapeutics, Inc. vs Inmune Bio, Inc. vs Viskase Holdings, Inc. vs Windtree Therapeutics Inc
| Latest fiscal year | Jasper Therapeutics, Inc. JSPR | Inmune Bio, Inc. INMB | Viskase Holdings, Inc. VISKRevenue covers only part of its income (partial revenue) | Windtree Therapeutics Inc WINTLast annual report: year ended 2024-12-31 |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2024-12-31 |
| Revenue | n/a | $50.0K | n/a | n/a |
| Revenue growth (YoY) | n/a | +257.1% | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | n/a | n/a |
| Net margin | n/a | n/m | n/a | n/a |
| Net income | -$75.80M | -$45.93M | -$3.41M | -$1.79M |
| EPS (Diluted) | -$3.95 | -$1.86 | -$0.07 | n/a |
| Operating cash flow | -$77.16M | -$22.58M | -$3.01M | -$15.40M |
| Free cash flow | n/a | -$23.62M | n/a | -$15.41M |
| Cash & equivalents | $28.69M | $24.75M | $42.57M | $1.78M |
| Total assets | $35.78M | $32.35M | $42.81M | $27.88M |
| Total liabilities | $31.63M | $8.83M | n/a | $14.70M |
| Shareholders' equity | $4.15M | $23.52M | -$2.52M | $10.00M |
| Return on year-end equity | n/m | -195.3% | n/a | -17.9% |
| Shares outstanding | 28.00M | 26.59M | 74.21M | 256.4K |
Revenue, most recent five fiscal years
| Fiscal year | Jasper Therapeutics, Inc. | Inmune Bio, Inc. | Viskase Holdings, Inc. | Windtree Therapeutics Inc |
|---|---|---|---|---|
| Latest | n/a | $50.0K Ended 2025-12-31 | n/a | $198.0K Ended 2019-12-31 |
| 1 year earlier | n/a | $14.0K Ended 2024-12-31 | n/a | $1.79M Ended 2018-12-31 |
| 2 years earlier | n/a | $155.0K Ended 2023-12-31 | n/a | $1.49M Ended 2017-12-31 |
| 3 years earlier | n/a | $374.0K Ended 2022-12-31 | n/a | $2.04M Ended 2016-12-31 |
| 4 years earlier | n/a | $181.0K Ended 2021-12-31 | n/a | $987.0K Ended 2015-12-31 |